Author Index to Volume 24

Abel LA, Ziegler AS. Smooth pursuit eye movements in schizophrenics-what constitutes quantitative assessment?, 747
Adams RN. *See* Oke AF
Adler LE, Pang K, Gerhardt G, Rose GM. Modulation of the gating of auditory evoked potentials by norepinephrine: pharmacologic evidence obtained using a selective neurotoxin, 179
Alcaron RD, Tolbert LC. One-carbon cycle metabolism in obsessive-compulsive disorder, 721-le
Alda M. Method for prediction of serum lithium levels, 218
Alda M. Predicting lithium levels, 952-le (response)
Altshuler LL. *See* Stevens CD
Altshuler LL, Cummings JL, Bartzokis G, Hill MA, May PRA. Lateral asymmetries of tardive dyskinesia in schizophrenia, 83
Anderson GM. *See* Riddle MA
Anraku S. *See* Yamada S
Archer RP, Struve FA, Ball JD, Gordon RA. EEG in borderline personality disorder, 731-le
Ardisson JL, *See* Souêtre E
Armario A, Restrepo C, Lopez-Calderon A. Effect of a chronic stress model of depression on basal and acute stress levels of LH and prolactin in adult male rats, 447
Arya BYT. *See* Sahu RN
Ashby CR Jr, Carr LA, Cook CL, Steptoe MM, Franks DD. Alteration of platelet serotonergic mechanisms and monoamine oxidase activity in premenstrual syndrome, 225
Asnis G. *See* Carson SW
Asnis GM, Eisenberg J, van Praag HM, Lemus CZ, Friedman JMH, Miller AH. The neuroendocrine response to fenfluramine in depressives and normal control, 117
Attias J. *See* Shalev A
Ball JD. *See* Archer RP
Balon R. *See* Pohl R
Balon R. *See* Yeragani VK
Barchas JD. *See* Faull KF
Barrera CM, Ruiz ZR, Dunlap WP. Uric acid: a participating factor in the symptoms of hyperactivity, 344
Bartkó G, Zádor G, Horváth S, Herczeg I. Neurologic soft signs in chronic schizophrenic patients: clinical correlates, 458
Bartzokis G. *See* Altshuler LL
Baumgartner A, Gräf K-J, Kürten I. Prolactin in patients with major depressive disorders and in healthy subjects. I. Cross-sectional study of basal and post-TRH and postdexamethasone prolactin levels, 249
Baumgartner A, Gräf K-J, Kürten I. Prolactin in patients with major depressive disorder and in healthy subjects. II. Longitudinal study of basal prolactin and post-TRH stimulated prolactin levels, 268
Baumgartner A, Gräf K-J, Kürten I. Prolactin in patients with major depressive disorder and in healthy subjects. III. Investigation of basal and post-TRH prolactin during different forms of acute and chronic psychological stress, 286
Baxter LR Jr. *See* Liston EH
Beasley CM Jr, Magnusson M, Garver DL. TSH response to TRH and haloperidol response latency in psychoses, 423
Becker J. *See* Zubenko GS
Becker RE. *See* Osman OT
Beckmann H. *See* Lesch K-P
Beckmann H. The neuropathology of schizophrenia, 953-le
Berchou R. *See* Pohl R
Berchou R. *See* Yeragani VK
Berger PA. *See* Faull KF
Berman S. *See* Thase ME
Berrettini WH. *See* Gershon ES
Beyer J. *See* Zubenko GS

Abbreviations
ed: Editorial
le: Letter to the Editor

Bierer L. *See* Davis KL
Bigelow L. *See* Stevens J
Bilder R. *See* Degreef G
Binder RL, Kazamatsuri H, Nishimura T, McNiel DE. Smoking and tardive dyskinesia, 364-le
Black DW, Winokur G, Hulbert J, Nasrallah A. Predictors of immediate response in the treatment of mania: the importance of comorbidity, 191
Bleich A. *See* Shalev A
Bloom E. *See* Irwin M
Bloomingdale K. *See* Zibrak JD
Bogerts B. *See* Falkai P
Bogerts B. *See* Stevens CD
Boll E. *See* Heuser I
Born J, Schenk U, Späth-Schwalbe E, Fehm HL. Influences of partial REM sleep deprivation and awakenings on nocturnal cortisol release, 801
Boutres NN, Hatch JP. Blink rate on routine EEGs: possible psychiatric significance, 717
Bowden CL. *See* Contreras SA
Bräunig P, Pollentier S, Rao ML. Increased serotinin after suicide attempt: coincidence or catharsis, 725-le
Brenner RP. *See* Cornelius JR
Brenner RP. *See* Trzepacz PT
Broderick PA, Jacoby JH. Serotonergic function in diabetic rats: psychotherapeutic implications, 234
Brown SA. *See* Irwin MR
Bruton CJ. *See* Roberts GW
Buckholtz NS, Davies AO, Rudorfer MV, Golden RN, Potter WZ. Lymphocyte beta adrenergic receptor function versus catecholamines in depression, 451
Burrows GD. *See* McIntyre IM
Buysse DJ, Reynolds CG III, Houck PR, Stack J, Kupfer DJ. Age of illness onset and sleep EEG variables in elderly depressives, 355
Byerley WF, Risch SC, Jachna J, Onstott P, Kripke DF. The effect of bright light on plasma prolactin, 843

Caligiuri MP, Harris MJ, Jeste DV. Quantitative analyses of voluntary orofacial motor control in schizophrenia and tardive dyskinesia, 787
Campbell CA, Peet M, Ward NI. Vanadium and other trace elements in patients taking lithium, 775
Caputo K. *See* Kramer MS
Carey RJ. *See* Lynch MR
Carr LA. *See* Ashby CR Jr
Carroll BJ. *See* Krishnan KRR
Carson SW, Halbreich U, Yeh CM, Asnis G, Goldstein S. Cortisol suppression per nanogram per milliliter of plasma dexamethasone in depressive and normal subjects, 569
Carson SW, Halbreich U, Yeh CM, Goldstein S. Altered plasma dexamethasone and cortisol suppressibility in patients with panic disorders, 56
Casanova M. *See* Stevens J
Casanova MF. *See* Stevens JR
Casas M, Ferre S, Guix T, Jane F. Theophylline reverses haloperidol-induced catalepsy in the rat. Possible relevance to the pharmacologic treatment of psychosis, 642
Casper RC, Pandy GN, Jaspan JB, Rubenstein AH. Hormone levels after oral glucose in bulimia and healthy controls, 663
Castellani S, Quillen MA, Vaughan DA, Hund MA, Le Vine WR. TSH and catecholamine response to TRH in panic disorder, 87
Cattarall WE. Tryptophan and bladder cancer, 733-le
Cerreta A. *See* Maj M
Chang W-H, Jaw S-S, Wu H-S. Time course of homovanillic acid in brain regions and drug levels in plasma and striatum in haloperidol-treated rats, 705
Chapman RM. *See* Schwarzkopf SB
Chui HC. *See* Schneider LS
Clark DC. *See* Pandey GN
Coccaro E. *See* Davis KL
Coffey CE, Figiel GS, Djang WT, Cress M, Saunders WB, Weiner RD. Leukoencephalopathy in elderly depressed patients referred for ECT, 143
Coffey CE, Weiner RD. ECT instrumentation, 361-le
Coffman G. *See* Trzepacz PT
Cohen DJ. *See* Riddle MA
Cohen MR. *See* Wolkowitz OM
Comaty JE. *See* Sharma RP
Conlon P, Trimble MR. A study of the corpus callosum in epileptic psychosis using magnetic resonance imaging, 857
Connelly P. *See* Naylor GJ
Conte G, Vita A, Sachetti E. Interepisodic

reliability of urinary MHPG excretion in major depression, 243
Contreras SA, Maas JW, Seleshi E, Bowden CL. Urine and plasma levels of dopamine metabolites in response to apomorphine and neuroleptics in schizophrenics, 818
Cook CL. *See* Ashby CR Jr
Cook EH Jr, Leventhal BL, Freedman DX. Free serotinin in plasma: autistic children and their first-degree relatives, 488
Cook RE. *See* Malin DH
Cornelius JR, Schulz SC, Brenner RP, Soloff PH, Ulrich RF. Changes in EEG mean frequency associated with anxiety and with amphetamine challenge in BPD, 587
Cowley DS, Dager SR, McClellan J, Roy-Byrne PP, Dunner DL. Response to lactate infusion in generalized anxiety disorder, 409
Cress M. *See* Coffey CE
Croot K. *See* Schuckit MA
Crow TJ. *See* Roberts GW
Crowe RR, Tsai LY, Murray JC, Patil SR, Quinn J. A study of autism using X chromosome DNA probes, 473
Crucian GP. *See* Malin DH
Cummings JL. *See* Altshuler LL

Dager SR. *See* Cowley DS
Daniels M. *See* Irwin M
Darcourt G. *See* Ardisson JL
Davidson M. *See* Davis KL
Davies AO. *See* Buckholtz NS
Davis BM. *See* Davis KL
Davis CL. *See* Rubinow DR
Davis J. *See* Zammit GK
Davis JM. *See* Sharma RP
Davis JM. *See* Pandey GN
Davis K. *See* Reite M
Davis KL, Davidson M, Yang R-K, Davis BM, Siever LJ, Mohs RC, Ryan T, Coccaro E, Bierer L, Targum SD. CSF somatostatin in Alzheimer's disease, depressed patients, and control subjects, 710
Dawson DV. *See* Krishnan KRR
Deck M. *See* Keilp JG
Degreef G, Mukherjee S, Bilder R, Schnur D. Season of birth and CT scan findings in schizophrenic patients, 461
Deicken RF, Verapamil treatment of premenstrual syndrome, 689
DiJohnson C. *See* Kramer MS
DeLisi LE. *See* Gershon ES
Dilsaver SC. Artificial light and nicotine subsensitivity, 437
Dilsaver SC, Smeltzer DJ. Smoking and tardive dyskinesia, 364-le
Djang WT. *See* Coffey CE
Doran AR. *See* Wolkowitz OM
Dunlap WP. *See* Barrerra CM
Dunner DL. *See* Cowley DS

Edrich J. *See* Reite M
Eisenberg J. *See* Asnis GM
Ekman R. *See* Lesch K-P
Ekman R. *See* Regnéll G
Ellinwood EH. *See* Heinz R
Elsenga S, Van den Hoofdakker RH. Body core temperature during total sleep deprivation in depressives, 531
Elston RC. *See* Hill EM
Eriksson I. *See* O'Brien CP

Falkai P. *See* Stevens CD
Falkai P, Bogerts B, Rozumek M. Limbic pathology in schizophrenia: the entorhinal region-a morphometric study, 515
Faull KF, Kraemer HC, Barchas JD, Berger PA. Probenecid monoamine test: correction, 960-le
Fawcett J. *See* Pandey GN
Fehm HL. *See* Born J
Feinstein SW, Trimble MR. State-dependent movement disorder, 945-le
Fernstrom MH, Massoudi M, Kupfer DJ. Fluoxamine and weight loss, 948-le
Ferre S. *See* Casas M
Figiel GS. *See* Coffey CE
Fink M. ECT instrumentation, 360-le
Finn P. *See* Schuckit MA
Fleischhacker WW. *See* Unterweger B
Fontaine R. *See* Primeau F
Fowler RC. *See* Rich CL
Frances A. *See* Keilp JG
Frank E. *See* Thase ME
Franks DD. *See* Ashby CR Jr
Freedman DX. *See* Cook EH Jr
Friedman JMH. *See* Asnis GM

Gaffney GR, Kuperman S, Tsai LY, Minchin S. Morphological evidence for brainstem involvement in infantile autism, 578
Gallant SA. *See* Hamilton JA

Garver DL. *See* Beasley CM Jr
George DT, Zerby A, Noble S, Nutt DJ. Panic attacks and alcohol withdrawal: can subjects differentiate the symptoms?, 240
Gerhardt G. *See* Adler LE
Gershon ES, Merrill CR, Goldin LR, DeLisi LE, Berrettini WH, Nurnberger JI Jr. HLA-A1 and schizophrenia 365-le (response)
Gibbons R. *See* Pandey GN
Glue P, Sellman JD, Joyce PR, Nicholls MG, Nutt DJ. The hypothermic response to clonidine is absent in alcohol withdrawal but returns in abstinence, 102
Gold EO. *See* Schuckit MA
Gold ME. *See* Liston EH
Gold PW. Stress-response neuromodulators, 371-ed
Goldberg SC. *See* Ross De
Golden RN. *See* Buckholtz NS
Goldin LR. *See* Gershon ES
Goldstein S. *See* Carson SW
Gordon RA. *See* Archer RP
Gorkin RA. *See* Kramer MS
Cormley GJ. *See* Lowy MT
Coryell W, Noyes R. HPA axis disturbance and treatment outcome in panic disorder, 762
Graf K-J. *See* Baumgartner A
Greden JF. *See* Meader-Woodruff JH
Greden JF. *See* Pande AC
Grunhaus L. *See* Meader-Woodruff JH
Grunhaus LJ. *See* Pande AC
Guttmacher LB. *See* Ringo JL
Guze BH. *See* Liston EH

Halbreich U. *See* Carson SW
Hamburger Sd. *See* Kruesi MJP
Hamilton JA, Gallant SA, Pinkel S. Urinary 6-hydroxymelatonin in menstruating women, 845
Hardin MT. *See* Riddle MA
Harris B, Read GF, Walker RF, Riad-Fahmy D. Salivary cortisol and adrenal function, 954-le
Harris MJ. *See* Caligiuri MP
Haskett RF. *See* Meader-Woodruff JH
Haskett RF. *See* Pande AC
Hatch JP. *See* Boutros NN
Heinz R, Rayasam K, Krishnan KRR, Wingfield M, Irigaray P, Ellinwood EH. MRI scans in patients with tardive dyskinesia, 852
Herczeg I. *See* Bartkó G
Herman R. Nocturnal panic in a depressed patient: pathophysiologic implications, 432
Heuser I, von Bardeleben U, Boll E, Holsboer F. Response to ACTH and cortisol to human corticotropin-releasing hormone after short term abstention from alcohol abuse, 316
Heyman A. *See* Krishnan KRR
Hill EM, Wilson AF, Elston RC, Winokur G. Evidence for possible linkage between genetic markers and affective disorders, 903
Hill MA. *See* Altshuler LL
Hill MR. *See* Ross DE
Ho L. *See* Castellani S
Holsboer F. *See* Heuser I
Holsboer F. *See* von Bardeleben U
Horváth S. *See* Bartko G
Houck PR. *See* Buysse DJ
Houck PR. *See* Thase ME
House JD. *See* Kronfol Z
Howard TL. *See* Irwin MR
Howell JR. *See* Thase ME
Hubert J. *See* Black DW
Huff FJ. *See* Zubenko Gs
Huff FJ, Reiter CT, Rosen J, Peters J, van Kammen DP. No effect of haloperidol on cerebrospinal fluid acetylcholinesterase in patients with schizophrenia, 701
Hund MA. *See* Castellani S

Inanago K. *See* Yamada S
Irigaray P. *See* Heinz R
Irwin M, Daniels M, Risch SC, Bloom E, Weiner H. Plasma cortisol and natural killer cell activity during bereavement, 173
Irwin MR, Risch SC, Brown SA, Howard TL, Smith TL, Knapp S, Schuckit MA. Urinary free cortisol excretion in depressed alcoholic patients, 713
Izumiya Y. *See* Kiriike N

Jachna J. *See* Byerley WF
Jacobsen P. *See* Keilp JG
Jacoby JH. *See* Broderick PA
Jane F. *See* Casas M
Janicak PG. *See* Sharma RP
Jankowski W. *See* Yeragani VK
Jarrett DB, Miewald JM, Kupfer DJ. Acute changes in sleep-related hormone secretion of depressed patients following oral imipramine, 541
Jaspan JB. *See* Casper RC
Jaw S-S. *See* Chang W-H

Jennings JR. *See* Thase ME
Jensen WA. *See* Zibrak JD
Jeste DV. *See* Caligiuri MP
Jiminez M. *See* Schwarzkopf SB
Joyce PR. *See* Glue P

Kahn J-P. *See* Rubinow DR
Kalinowsky LB. ECT instrumentation, 361-le
Kane CF. *See* Schwarzkopf SB
Karkkainen J, Raisanen M, Naukkarien H, Spoov J, Rimon R. Urinary excretion of free bufotenin by psychiatric patients, 441
Karpiak SE. *See* Mahadik SP
Kasper S, Sack DA, Wehr TA, Kick H, Voll G, Vieira A. Nocturnal TSH and prolactin secretion during sleep deprivation and prediction of antidepressant response in patients with major depression, 631
Kawakita Y. *See* Kiriike N
Kazamatsuri H. *See* Binder RL
Keilp JG, Sweeney JA, Jacobsen P, Solomon C, St. Louis L, Deck M, Frances A, Mann JJ. Cognitive impairment in schizophrenia: specific relations to ventricular size and negative symptomology, 47
Kemali D. *See* Maj M
Kempenaers C, Kerkhofs M, Linkowski P, Mendlewicz J. Sleep EEG variables in young schizophrenic and depressive patients, 833
Kerkhofs M. *See* Kempenaers C
Khanna S. Obsessive-compulsive disorder: is there a frontal lobe dysfunction? 602 (comment)
Kick H. *See* Kasper S
Kiriike N, Izumiya Y, Nishiwaki S, Maeda Y, Nagata T, Kawakita Y. TRH test and DST in schizoaffective mania, mania and schizophrenia, 415
Klein G. *See* Unterweger B
Kling M. *See* Rubinow DR
Knapp S. *See* Irwin MR
Kojima H. *See* Yamada S
Koponen H, Repo E, Lepola U. Neuroleptic malignant syndrome, 943-le
Korenovsky A. *See* Mahadik SP
Korpi ER. Glutamine and suicide, 723-le (reply)
Kotler M. *See* Shalev A
Kraemer HC. *See* Faull KF
Kramer J. *See* Kuperman S
Kramer MS. Caputo K, DiJohnson C, Maldonado L, Mirow A, Sheves P, Sholevar F. Negative trial of nifedipine in depression, 958-le
Kramer MS, Gorkin RA, DiJohnson C, Sheves P. Propranolol in the treatment of neuroleptic-induced akathisia (NIA) in schizophrenics: a double-blind, placebo-controlled study, 823
Krebs B. *See* Souêtre E
Kripke DF. *See* Byerley WF
Krishnan KRR. *See* Heinz R
Krishnan KRR, Heyman A, Ritchie JC, Utley CM, Dawson DV, Rogers H. Depression in early-onset Alzheimer's disease: clinical and neuroendocrine correlates, 937
Krishnan KRR, Ritchie JC, Manepalli AN, Nemeroff CB, Carroll BJ. Adrenocortical sensitivity to ACTH in humans, 105
Kronful Z, House JD. Immune function in mania, 341
Kruesi MJP, Swedo SE, Hamburger SD, Potter WZ, Rapaport JL. Concentration gradient of CSF monoamine metabolites in children and adolescents, 507
Krugler T. *See* Pande AC
Kuperman S. *See* Gaffney GR
Kuperman S, Kramer J, Loney J. Enzyme activity and behavior in hyperactive children grown up, 375
Kupfer DJ. *See* Buysse DJ
Kupfer DJ. *See* Fernstrom MH
Kupfer DJ. *See* Jarrett DB
Kupfer DJ. *See* Thase ME
Kürten I. *See* Baumgartner A

Lamberti JS. *See* Schwarzkopf SB
Laev H. *See* Mahadik SP
Larson EW, Newman DC, Lin S-C, Maruta T. Cortisol in major depression, 957-le
Laruelle M, Vanisberg M-A, Maloteaux J-M. Regional and subcellular localization in human brain of [^{3}H] paroxetine binding, a marker of serotinin uptake sites, 299
Laux G. *See* Lesch K-P
Leckman JF. *See* Riddle MA
Lenus CZ. *See* Asnis GM
Lepola U. *See* Koponen H
Lesch K-P, Widerlov E, Ekman R, Laux G, Schulte HM, Pfuller H, Beckmann H. Delta sleep-inducing peptide response to human corticotropin-releasing hormone (CRH) in major depressive disorder-comparison with CRH-induced corticotropin and cortisol secretion, 1612
Leventhal BL. *See* Cook EH Jr

Le vine WR. *See* Castellani S
Lin S-C. *See* Larson EW
Linkowski P. *See* Kempenaers C
Liston EH, Guze BH, Baxter LR Jr, Richeimer SH, Gold ME. Motor versus EEG seizure duration in ECT, 94
Locasio JJ. *See* Meltzer HY
Loney J. *See* Kuperman S
López-Calderon A. *See* Armario A
Lowy MT. *See* Meltzer HY
Lowy MT, Reder AT, Gormley GJ, Meltzer HY. Comparison of in vivo and in vitro glucocorticoid sensitivity in depression: relationship to the Dexamethasone Suppression Test, 619
Lycaki H. *See* Pohl R
Lynch MR, Carey RJ. Sensitization of chronic neuroleptic behavioral effects, 950-le

Maas JW. *See* Contreras SA
Maeda Y. *See* Kiriike N
Magnusson M. *See* Beasley CM Jr
Mahadik SP, Laev H, Korenovsky A, Karpiak SE. Haloperidol alters rat CNS cholinergic system: enzymatic and morphologic analysis, 199
Maj M, Mastronardi P, Cerreta A, Romano M, Mazzarella B, Kempli D. Changes in platelet ^{3}H-imipramine binding in depressed patients receiving electroconvulsive therapy, 469
Maldonado L. *See* Kramer MS
Malin DH, Murray JB, Crucian GP, Schweitzer FC, Cook RE, Skolnick MH. Auricular microelectrostimulation: naloxone-reversible attenuation of opiate abstinence syndrome, 886
Maloteaux J-M. *See* Laruelle M
Manepalli AN. *See* Krishnan KRR
Mann JJ. *See* Keilp JG
Markianos M. *See* Papakostas Y
Maruta T. *See* Larson EW
Massoudi M. *See* Fernstrom MH
Mastronardi P. *See* Maj M
May PRA. *See* Altshuler LL
Mazzarella B. *See* Maj M
McIntyre IM, Burrows GD, Norman TR. Suppression of plasma melatonin by a single dose of the benzodiazepine alprazolam in humans, 108
McClellan J. *See* Cowley DS
McLellan AT. *See* O'Brien CP
McNiel DE. *See* Binder RL
Meader-Woodruff JH, Greden JF, Grunhaus L, Haskett Rf. Dexamethasone Suppression Test status and severity of depression, 693
Meltzer HY. *See* Lowy MT
Meltzer HY. *See* Zurieck JL
Meltzer HY, Lowy MT, Locascio JJ. Platelet MAO activity and the cortisol response to dexamethasone in major depression, 129
Mandlewicz J. *See* Kempenaers C
Merriam AE. Withdrawal NMS after drug treatment, 368-le
Merrill CR. *See* Gershon Es
Metzer WS, Newton JEO, Paige SR. HLA-A1 and schizophrenia, 365-le
Miewald JM. *See* Jarrett DB
Miller AH. *See* Asnis GM
Minchin S. *See* Gaffney Gr
Mirow A. *See* Kramer MS
Mohs RC. *See* Davis KL
Moline ML, Monk TH. Sleeping and napping-cognitive influences on the biological clock, 838
Monk TH. *See* Moline ML
Motooka MS. *See* Rich CL
Mukherjee S. *See* Degreef G
Müller OA. *See* von Bardeleben U
Murray JB. *See* Malin DH
Murray JC. *See* Crowe RR

Nagata T. *See* Kiriike N
Nasrallah A. *See* Black DW
Nasrallah HA. *See* Schwarzkopf SB
Naukkarinen H. *See* Kärkkäinen J
Naylor GJ, Smith AHW, Connelly P. Methylene blue in mania, 941-le
Nemeroff CB. *See* Krishnan KRR
Newman DC. *See* Larson EW
Newton JEO. *See* Metzer WS
Nicholls MG. *See* Glue P
Nishi S. *See* Yamada S
Nishimura T. *See* Binder RL
Nishiwaki S. *See* Kiriike N
Noble S. *See* George DT
Nofzinger EA. *See* Schmidt HS
Norman TR. *See* McIntyre IM
Noyes R. *See* Coryell W
Nurnberger JI. *See* Gershon ES
Nutt DJ. *See* George Dt
Nutt DJ. *See* Glue P
Nyberg F. *See* O'Brien CP

O'Brien CP, Terenius LY, Nyberg F, McLellan AT, Eriksson I. Endogenous opioids in cerebrospinal fluid of opioid-dependent humans, 649
Ochs AL. *See* Ross DE
Oke AF, Adams RN, Winblad B, von Knorring L. Elevated dopamine/norepinephrine ratios in thalami of schizophrenic brains, 79
Onstott P. *See* Byerley WF
Ort SI. *See* Riddle MA
Ortiz A. *See* Pohl R
Ortiz A. *See* Yeragani VK
Osman OT, Becker RE. Neuroleptics and their metabolites binding to alpha$_1$ and D_2 receptors, 815

Padmashree TS. *See* Sahu RN
Paige SR. *See* Metzer WS
Pande AC, Krugler T, Haskett RF, Greden JF, Grunhaus LJ. Predictors of response to electroconvulsive therapy in major depressive disorder, 91
Pandey GN. *See* Sharma RP
Pandey GN, Fawcett J, Gibbons R, Clark DC, Davis JM. Platelet monoamine oxidase in alcoholism, 15
Pandey RS. *See* Sahu RN
Pandurangi AK. *See* Ross DE
Pandy GN. *See* Casper RC
Pang K. *See* Adler LE
Papakostas Y, Markianos M, Stefanis C. Methysergide reduces the prolactin response to ECT, 465
Patil Sr. *See* Crowe RR
Peet M. *See* Campbell Ca
Peters J. *See* Huff FJ
Peterson J. *See* Sharma RP
Pfüller H. *See* Lesch K-P
Pickar D. *See* Wolkowitz OM
Pinkel S. *See* Hamilton JA
Pohl R. *See* Yeragani VK
Pohl R, Yeragani VK, Balon R, Rainey JM, Lycaki H, Ortiz A, Berchou R, Weinberg P. Isoproterenol-induced panic attacks, 891
Polich J. *See* Schuckit MA
Pollentier S. *See* Braunig P
Post RM. *See* Rubinow DR
Potter WZ. *See* Buckholtz NS
Potter WZ. *See* Kruesi MJP
Primeau F, Fontaine R. GABAergic agents and panic disorder, 942-le
Pringuey D. *See* Souêtre E

Quillen MA. *See* Castellani S
Quinn J. *See* Crowe RR

Rainey JM. *See* Pohl R
Rainey JM. *See* Yeragani VK
Räisänen M. *See* Kärkkäinen J
Rao ML. *See* Bräunig P
Rapoport JL. *See* Kruesi MJP
Rayasam K. *See* Heinz R
Read GF. *See* Harris B
Reder AT. *See* Lowy MT
Regńell G, Widerlöv E, Ekman R. Delta sleep-inducing peptide in CSF of patients with affective illness is elevated by lithium treatment, 112
Reite M, Teale P, Zimmerman J, Davis K, Whalen J, Edrich J. Source origin of a 50-msec latency auditory evoked field component in young schizophrenic men, 495
Reiter CT. *See* Huff FJ
Repo E. *See* Koponen H
Restrepo C. *See* Armario A
Reynolds CF III. *See* Buysse DJ
Reynolds CF III. *See* Thase ME
Riad-Fahmy D. *See* Harris B
Rich CL, Motooka MS. Fowler RC, Young D. Suicide in psychotics, 595
Richeimer SH. *See* Liston EH
Riddle MA, Leckman JF, Anderson GM, Ort SI, Hardin MT, Stevenson J, Cohen DJ. Plasma MHPG: within- and across-day stability in children and adults with Tourette's syndrome, 391
Rimon R. *See* Kärkkäinen J
Ringo JL, Guttmacher LB. Amnesia for the McCollough effect following unilateral electroconvulsive therapy: implications for laterality, 384
Risch SC. *See* Byerley WF
Risch SC. *See* Irwin M
Risch SC. *See* Irwin MR
Ritchie JC. *See* Krishnan KRR
Rix H. *See* Souêtre E
Roberts GW, Bruton CJ, Crow TJ. Gliosis in schizophrenia, 729-le
Rogers H. *See* Krishnan KRR
Romano M. *See* Maj M
Rose GM. *See* Adler LE

Rosen J. *See* Huff FJ
Rosenbaum AH. *See* Zammit GK
Ross DE, Ochs AL, Hill MR, Goldberg SC, Pandurangi AK, Winfrey CJ. Erratic eye tracking in schizophrenic patients as revealed by high resolution techniques, 675
Roth T. *See* Zammit GK
Roy-Byrne PP. *See* Cowley DS
Rozendaal N. *See* van den Bosch RJ
Rozumek M. *See* Falkai P
Rubenstein AH. *See* Casper RC
Rubin RT. Glutamine and suicide 723-le
Rubinow DR, Davis CL, Kahn J-P, Kling M, Post RM. Salivary cortisol and adrenal function, 955-le (response)
Rudin DO. Conflict of interest, 724-le
Rudorfer MV. *See* Buckholtz NS
Ruiz ZR. *See* Barrera CM
Ryan T. *See* Davis KL

Sacchetti E. *See* Conte G
Sack DA. *See* Kasper S
Sahu RN, Pandey RS, Subhash MN, Arya BYT, Padashree TS, Scrinivas KN. CSF zinc in Alzheimer's type dementia, 480
St. Louis L. *See* Keilp JG
Salvati E. *See* Souêtre E
Saunders WB. *See* Coffey Ce
Schenk U. *See* Born J
Schmidt HS, Nofzinger EA. Short REM latency in impotence without depression, 25
Schneider LS, Chui HC, Severson JA, Sloane RB. Decreased platelet ^{3}H-imipramine binding in Parkinson's disease, 348
Schnur D. *See* Degreef G
Schuckit MA. *See* Irwin MR
Schuckit MA, Gold EO, Croot K, Finn P, Polich J. P300 latency after ethanol ingestion in sons of alcoholics and in controls, 310
Schulte HM. *See* Lesch K-P
Schulz SC. *See* Cornelius JR
Schwarzkopf SB, Chapman RM, Jiminez M, Treglia L, Kane CF, Lamberti JS, Nasrallah HA. Familial and sporadic schizophrenia: visual evoked potential differences, 828
Schweitzer FC. *See* Malin DH
Seleshi E. *See* Contreras SA
Sellman JD. *See* Glue P
Severson JA. *See* Schneider LS
Shahar A. *See* Shalev A
Shalev A, Attias J, Bleich A, Shulman H, Kotler M, Shahar A. Audiologic evaluation of non-alcoholic, drug-free posttraumatic stress disorder patients, 522
Sharma RP, Pandey GN, Janicak PG, Peterson J, Comaty SE, Davis JM. The effect of diagnosis and age on the DST: a metaanalytic approach, 555
Sherer MA. Intravenous cocaine: psychiatric effects, biological mechanisms, 865
Sheves P. *See* Kramer MS
Sholevar F. *See* Kramer MS
Shulman H. *See* Shalev A
Siever LJ. *See* Davis KL
Skolnick MH. *See* Malin DH
Sloane RB. *See* Schneider LS
Smeltzer DJ. *See* Dilsaver SC
Smith AHW. *See* Naylor GJ
Smith TL. *See* Irwin MR
Soloff PH: *See* Cornelius JR
Solomon C. *See* Keilp JG
Sommer BR, Wolkowitz OM. RBC folic acid levels and cognitive performance in elderly patients: a preliminary report, 352
Souêtre E, Salvati E, Rix H, Pringuey D, Krebs B, Ardisson JL, Darcourt G. Effect of recovery on the cortisol circadian rhythm of depressed patients, 336
Späth-Schwalbe E. *See* Born J
Spoov J. *See* Kärkkäinen J
Srinivas KN. *See* Sahu RN
Stack J. *See* Buysse DJ
Stalla GK. *See* von Bardeleben U
Stefanis C. *See* Papakostas Y
Stein MB, Uhde TW. Cortisol response to clonidine in panic disorder: comparison with depressed patients and normal controls, 322
Stein J. Manic tempo misperceptions, 366-le
Steptoe MM. *See* Ashby CR Jr
Stevens CD, Altshuler LL, Bogerts B, Falkai P. Quantitative study of gliosis in schizophrenia and Huntington's chorea, 697
Stevens J, Casanova M, Bigelow L. Gliosis in schizophrenia, 727-le
Stevens JR, Casanova MF. Is there a neuropathology of schizophrenia?, 123-ed
Stevens JR, Casanova MF. The neuropathology of schizophrenia, 954-le (response)
Stevenson J. *See* Riddle MA
Stokes P. *See* Zammit GK
Struve FA. *See* Archer RP
Subhash MN. *See* Sahu RN
Swartz CM. Predicting lithium levels, 951-le

Swedo SE. *See* Kruesi MJP
Sweeney JA. *See* Keilp JG

Takamuki K. *See* Yamada S
Targum SD. *See* Davis KL
Teale P. *See* Reite M
Teply I. *See* Zubenko GS
Terenius LY. *See* O'Brien CP
Thase ME, Reynolds CF III, Jennings JR, Frank E, Howell JR, Houck P, Berman S, Kupfer DJ. Nocturnal penile tumescence is diminished in depressed man, 33
Tolbert LC. *See* Alcaron Rd
Treglia L. *See* Schwarzkopf SB
Trimble MR. *See* Conlon P
Trimble MR. *See* Feinstein SW
Trzepacz PT, Brenner RP, Coffmann G, van Thiel H. Delirium in liver transplantation candidates: discriminant analysis of multiple test variables, 3
Tsai LT. *See* Crowe RR
Tsai LY. *See* Caffney GR
Tsutsumi T. *See* Yamada S
Tu J-B. Neuropsychopharmacology and genetics, 493-ed

Uhde TW. *See* Stein MB
Ulett GA. Acupuncture update, 247-ed
Ulrich Rf. *See* Cornelius JR
Unterweger B, Klein G, Fleischhacker WW. Plasma exchange for cerebral lupus erythematosus, 946-le
Utley CM. *See* Krishnan KRR

van den Bosch RJ, Rozendaal N. Subjective cognitive dysfunction, eye tracking, and slow brain potentials in schizophrenic and schizoaffective patients, 741
Van den Hoofdakker RH. *See* Elsenga S
van Kammen DP. *See* Huff FJ
van Praag HM. *See* Asnis GM
van Praag HM. The teaching of psychiatry: a statue without a socle, 863-ed
Van Sweden B. Rebound antidepressant cardiac arrhythmia, 363-le
van Thiel H. *See* Trzepacz PT
Vanisberg M-A. *See* Laruelle M
Vaughan DA. *See* Castellani S
Viera A. *See* Kasper S
Vita A. *See* Conte G
Voll G. *See* Kasper S
von Bardeleben U. *See* Heuser I
von Bardeleben U, Stalla GK, Müller OA, Holsboer F. Blunting of ACTH response to human CRH in depressed patients is avoided by metyrapone pretreatment, 782
von Bardeleben U, Wiedemann K, Stalla GK, Müller OA, Holsboer F. Exaggerated corticotrophic cell response to human corticotropin-releasing hormone in two patients during long-term carbamazepine treatment, 331
von Knorring L. *See* Oke AF

Walker Rf. *See* Harris G
Ward NI. *See* Campbell Ca
Weaver L. ECT instrumentation, 362-le (response)
Wehr TA. *See* Kasper S
Weinberg P. *See* Pohl R
Weiner H. *See* Irwin M
Weiner RD. *See* Coffey CE
Whalen J. *See* Reite M
Widerlöv E. *See* Lesch K-P
Widerlöv E. *See* Regnell G
Wiedemann K. *See* von Bardeleben U
Wilson Af. *See* Hill EM
Winblad B. *See* Oke AF
Winfrey CJ. *See* Ross DE
Wingfield M. *See* Heinz R
Winokur G. *See* Black DW
Winokur G. *See* Hill EM
Wise TN. *See* Wolkowitz OM
Wolkowitz OM. *See* Sommer BR
Wolkowitz OM, Doran AR, Cohen MR, Cohen RM, Wise TN, Pickar D. Single-dose naloxone acutely reduces eating in obese humans: behavioral and biochemical effects, 483
Wortis J. Remembering Gjessing: 1887–1959, 1-ed
Wortis J. Struwwelpeter Heinrich Hoffman (1809–1984), 615-ed
Wu H-S. *See* Chang W-H

Yamada S, Kojima H, Yokoo H, Tsutsumi T, Takamuki K, Anraku S, Nishi S, Inanaga K. Enhancement of dopamine release from striatal slices of rats that were subchronically treated with methamphetamine, 399
Yang R-K. *See* Davis KL

Yeh C-M. *See* Carson SW
Yeragani VK. *See* Pohl R
Yeragani VK, Pohl R, Balon R, Jankowski W. Nicotine and panic attacks, 365-le
Yeragani VK, Pohl R, Balon R, Rainey JM, Berchou R, Ortiz A. Sodium lactate infusions after treatment with tricyclic antidepressants: behavioral and physiological findings, 767
Yokoo H. *See* Yamada S
Young D. *See* Rich CL

Zádor G. *See* Bartkó G
Zammit GK, Rosenbaum AH, Stokes P, Davis J, Zorick F, Roth T. Biological differences in endogenous depressive placebo response versus nonresponders: Dexamethasone Suppression Test and sleep EEG data, 97
Zerby A. *See* George DT
Zibrak JD, Jensen Wa, Bloomingdale K. Aspiration pneumonitis following electroconvulsive therapy in patients with gastroparesis, 812
Ziegler AS. *See* Abel LA
Ziegler MG. *See* Castellani S
Zimmerman J. *See* Reite M
Zorick F. *See* Zammit GK
Zubenko GS, Huff FJ, Becker J, Beyer J, Teply I. Cognitive function and platelet membrane fluidity in Alzheimer's disease, 925
Zubenko GS, Teply I. Longitudinal study of platelet membrane fluidity in Alzheimer's disease, 918
Zurieck JL, Meltzer HY. Platelet MAO activity in hallucinating and paranoid schizophrenics: a review and meta-analysis, 63

Subject Index to Volume 24

Acetylcholinesterase
  cerebrospinal fluid activity, in schizophrenia, haloperidol effects on, 701
ACTH. *See* Adrenocorticotropic hormone
Acupuncture
  update, 247-ed
Adrenal function
  salivary cortisol and, 954-le, 955-le (response)
Adrenocortical hormone
  response to, human corticotropin-releasing hormone, metyrapone effects on, 782
Adrenocorticotropic hormone (ACTH)
  adrenocortical sensitivity to, 105
  response to human corticotropin releasing hormone, alcohol abstention and, 316
Affective disorders
  linkage with genetic markers, 903
  seasonal, 437
Age
  effect on DST, 555
Agorophobia
  alprazolam for, 762
Akathisia
  neuroleptic-induced, propranolol for, 823
Alcohol
  abstention from, response of ACTH and cortisol to human corticotropin-releasing hormone and, 316
  withdrawal
  hypothermic response to clonidine in, 102
  panic disorder in, 234
Alcoholism
  depression in, urinary free cortisol excretion in, 713
  P 300 latency and, 310
  platelet monoamine oxidase activity in, 15
  short REM latency in, 25
Alpha$_1$ receptors
  neuroleptic binding to, 815
Alprazolam
  for panic disorder, 762
  suppression of plasma melatonin in, 108
Alzheimer's disease
  cognitive function in, 925
  CSF zinc in, 480
  early-onset, depression in, 937
  platelet membrane fluidity in, 918, 925
  somatostatin CSF levels in, 710
Amnesia
  for McCullough effect, following electroconvulsive therapy, 384
Amphetamine
  auditory evoked potentials and, 179
  EEG mean frequency changes associated with, 587
Antidepressants
  cardiac arrhythmia and, 363-le
  tricyclic. *See* Tricyclic antidepressants
Antipsychotic drugs
  levels, homovanillic acid and, 705
Anxiety
  EEG mean frequency changes associated with, 587
  response to lactate infusion in, 409
Apomorphine
  dopamine metabolites level in response to, 818
Arrhythmia. *See* Cardiac arrhythmia
Audiologic evaluation
  in posttraumatic stress disorder patient, 522
Auditory evoked potentials
  modulation of gating, by norepinephrine, 179
  50-msec latency component, in schizophrenic males, 495
Auricle
  microelectrostimulation, opiate abstinence syndrome, attenuation of, naloxone reversible, 886
Autism
  free serotinin in plasma and, 488
  infantile, brainstem involvement in, 578
  study of, using X chromosome DNA probes, 473

Bereavement
  plasma cortisol and natural killer cell activity in, 173
Beta adrenergic receptor

Abbreviations
ed: Editorial
le: Letter to the Editor

lymphocyte, in depression, versus catecholamine, 451
Biological clock
influences of sleeping and napping on, 838
Birth
seasonality of, schizophrenia and, 461
Bladder
cancer, tryptophan and, 733-le
Blink rate
on routine EEG, 717
Borderline personality disorder
amphetamine challenge in, EEG mean frequency changes associated with, 587
EEG in, 731-le
Brain
dysfunction, asymmetric, in schizophrenia with tardive dyskinesia, 83
potentials, in schizophrenic and schizoaffective patients, 741
Brainstem
involvement in infantile autism, 578
Bufotenin
urinary excretion of, 441
Bulimia
glucose loading in, glucose tolerance and hormonal response following, 663

Carbamazepine
corticotrophic cell response to human corticotropin-releasing hormone and, 331
Cardiac arrhythmia
antidepressant withdrawal and, 363-le
Catalepsy
haloperidol-induced, theophylline reversal of, 642
Catecholamines
in depression, versus lymphocyte beta adrenergic function, 451
response to TRH in panic disorder, 87
Cerebral ventricle
size, cognitive impairment in depression and, 47
Cerebrospinal fluid (CSF)
opioids in, 649
Clonidine
cortisol response to, in panic disorder, 322
hypotheric response to, in alcohol withdrawal, 102
Cocaine
intravenous, psychiatric effects and biological mechanisms, 865
Cognitive function
in Alzheimer's disease, 925
in elderly, folic acid and, 352
in schizophrenia and schizoaffective patients, 47, 741
Colinergic system
central nervous system, haloperidol alteration of, 199
Computed tomography
abnormal, season of birth in schizophrenia and, 461
Conflicts of interest, 724-le
Corpus callosum
in epileptic psychosis, 857
Correction, 492
Probenecid monoamine test, 960-le
Correspondence
Conflicts of interest, 724
Cortisol in major depression, 957
ECT instrumentation, 360
EEG in borderline personality disorder, 731
Fluvoxamine and weight loss, 948
GABAergic agents and panic disorder, 942
Gliosis, in schizophrenia, 727
Glutamine and suicide, 723
Increased serotinin after a suicide attempt: coincidence or catharsis, 725
Manic tempo misperceptions, 366
Methylene blue in mania, 941
Negative trial of nifedipine in depression, 958
Neuroleptic malignant syndrome, 943
The neuropathology of schizophrenia, 953, 954 (response)
Nicotine and panic attacks, 365
One-carbon cycle in obsessive-compulsive disorder, 721
Plasma exchange for cerebral lupus erythematosus, 946
Predicting lithium levels, 951, 952 (response)
Probenecid monoamine test: correction, 960
Rebound antidepressant cardiac arrhythmia, 363
Salivary cortisol and adrenal function, 954, 955 (response)
Sensitization of chronic neuroleptic behavioral effects, 950
Smoking and tardive dyskinesia, 364
State-dependent movement disorder, 945
Tryptophan and bladder cancer, 733
Withdrawal NMS after drug treatment, 368
Corticotrophic cell
response to human corticotropin-releasing hormone, carbamazepine and, 331
Corticotrophin-releasing factor (CRF)
ACTH response to, 105
alcohol abstention and, 316
metyrapone effects on, 782

cortisol response to, alcohol abstention and, 316
delta sleep-inducing peptide response to, in depression, 162
human, corticotrophic cell response to, carbamazepine and, 331
Cortisol
circadian rhythm, in depression, 336
in depression, 957-le
plasma levels, in bereavement, 173
release, nocturnal, REM sleep deprivation and awakenings effect on, 801
response to ACTH, in depression, 105
response to clonidine, in panic disorder, 322
response to dexamethasone, in depression, 129
response to human corticotropin releasing hormone, alcohol abstention and, 316
salivary, adrenal function and, 954-le
suppressibility, in panic disorders, 56
suppression by dexamethasone, 569
urinary free excretion, in depressed alcoholic patients, 713

D_2 receptors
neuroleptic binding to, 815
Delirium
in liver transplantation candidates, 3
Delta sleep-inducing peptide
CSF levels, effect of lithium on, 112
response to corticotropin-releasing hormone, in depression, 162
Depression
ACTH response to human CRH in, metyrapone and, 782
changes in platelet ^{3}H-imipramine binding in, electroconvulsive therapy and, 469
chronic stress model of, effect on LH and prolactin levels, 447
cortisol in, 957-le
cortisol circadian rhythm in, 336
cortisol response to clinidine in, 322
delta sleep-inducing peptide response to corticotropin-releasing hormone in, 162
in early-onset Alzheimer's disease, 937
glucocorticoid sensitivity in, 619
lymphocyte beta adrenergic function versus catecholamines in, 451
MAO activity and cortisol response to dexamethasone in ,129
neuroendocrine response to fenfluramine in, 117
nifedipine in, negative trial of, 958-le
nocturnal panic in, 432
nocturnal penile tumescence in, 33
prolactin levels in, 249, 268, 286
response to electroconvulsive therapy in, predictors of, 91
severity of, Dexamethasone Suppression Test status and, 693
sleep EEG variables in, 833
somatic vs. nonsomatic treatment, Dexamethasone Suppression test and sleep EEG data, 97
somatostatin CSF levels in, 710
total sleep deprivation in, body core temperature and, 531
urinary MHPG excretion in, 243
Dexamethasone
cortisol suppression by, 569
disposition, in panic disorders, 56
MAO activity and cortisol response to, in depression, 129
prolactin levels and, 249
Dexamethasone Suppression Test
depression in early-onset Alzheimer's disease, and, 937
drug treatment response in depression and, 97
effect of diagnosis and age on, 555
glucocorticoid sensitivity in depression and, 61
in panic disorder, 762
in schizoaffective mania, mania, and schizophrenia, 415
status, severity of depression and, 693
Diabetes
serotonergic function in, 234
Diagnosis
effect on DST, 555
Dopamine
metabolites, levels, in response to apomorphine and neuroleptics, in schizophrenia, 818
norepinephrine ratios, in schizophrenic brain, 79
release, methamphetamine effects on, 399
Drug treatment
withdrawal, NMS and, 369-le

ECT *See* Electroconvulsive therapy
Editorial
Acupuncture update, 247
Is there a neuropathology of schizophrenia?, 123
Neuropsychopharmacology and genetics, 493
Obsessive compulsive disorder: is there a frontal lobe dysfunction?, 602
Remembering Gjessing, 1887-1959, 1
Stress-responsive neuromodulators, 371
Struwwelpeter Heinrich Hoffman, 615
Teaching of psychiatry, 863
EEG *See* Electroencephalogram

Elderly
cognitive performance, folic acid levels and, 352
depressives
age of onset and sleep EEG variables in, 355
leukoencephalopathy in, 143
Electroconvulsive therapy (ECT)
changes in platelet ^{3}H-imipramine binding and, 469
gastroparesis and, aspiration pneumonitis following, 812
instrumentation, 360-le
prolactin response to, effect of methysurgide on, 465
response to, in depressive disorders, predictors of, 91
seizure duration in, 94
Electroencephalogram (EEG)
in borderline personality disorder, 731-le
frequency changes, anxiety and amphetamine associated, 587
routine, blink rate on, 717
sleep
drug treatment response in depression and, 97
in elderly depressives, 355
in schizophrenia and depression, 833
Entorhinal region
in schizophrenia, 515
Enzyme
activity, in hyperactive children grown up, 375
Epileptic psychosis, *See* Psychosis, epileptic
Eye
movements, in schizophrenics, 747
tracking, in schizophrenic and schizoaffective patients, 675, 741

Fenfluramine
neuroendocrine response to, 117
Fluvoxamine
weight loss and, 948-le
Folic acid
red blood cell levels, in elderly, cognitive performance and, 352
Frontal lobe
dysfunction, in obsessive-compulsive disorder, 602-ed

GABA. *See* Gamma-aminobutyric acid
Gamma-aminobutyric acid (GABA)
agents, panic disorder and, 742-le
Gastroparesis
electroconvulsive therapy and, 812
Genetic markers
linkage with affective disorders, 903
Genetics
neuropharmacology and, 493-ed
Gjessing, Rolv, 1-ed
Gliosis
in schizophrenia and Huntington's chorea, 697, 727-le
Glucocorticoid
sensitivity, in depression, 619
Glucose
tolerance, in bulimia, 663
Glutamine
suicide and, 723-le

Haloperidol
alteration of CNS cholinergic system, 199
cocaine rush and, 865
effects on cerebrospinal fluid acetylcholinesterase, in schizophrenia, 701
-induced catalepsy, theophylline reversal of, 642
response latency, in psychoses, 423
time course of homovanillic acid and, 705
Hoffman, Struwwelpeter Heinrich, 615-ed
Homovanillic acid
time course of, in brain regions, antipsychotic drugs and, 705
Hormones
plasma levels, following glucose loading, in bulimia, 663
secretion, sleep-related changes in, effect of imipramine on, 541
Huntington's chorea, gliosis in, 697
HPA axis
in panic disorder, 762
6-Hydroxymelatonin
urinary levels, in menstruating women, 845
Hyperactivity
childhood, enzyme activity and behavior, in adulthood, 375
uric acid in, 344

Illness
onset, age of, in elderly depressives, 355
Imipramine
effect on sleep-related hormone secretion, 541
Immune function
in mania, 341
Isoproterenol
-induced panic attacks, 891

Lactate
-induced panic attacks, tricyclic anti-depressants and, 767
infusion, response to, in anxiety disorder, 409
Leukoencephalopathy

in elderly depressed, 143
Light
artificial, hypothermic response to nicotine and, 437
bright, plasma prolactin effects, 843
Limbic pathology
in schizophrenia, 515
Lithium
effects on trace element levels, 775
elevation of delta sleep-producing peptide levels by, 112
levels, predicting of, 951-le, 952-le (response)
serum levels, prediction of, 218
Liver transplantation
candidates, delirium in, 3
Lupus erythematosus
cerebral, plasma exchange for, 946-le
Luteinizing hormone
levels, effect of chronic stress model of depression on, 447

Magnetic resonance imaging (MRI)
of corpus callosum in epileptic psychosis, 857
of tardive dyskinesia, 852
Mania
immune function in, 341
methylene blue in, 941-le
tempo misperceptions in, 366-le
correction, 492
treatment, immediate response to, predictors of, 191
TRH test and DST in, 415
MAO *See* Monoamine oxidase activity
Melatonin
suppression of, by alprazolam, 108
Menstruation
urinary 6-hydroxymelatonin levels in, 845
Methamphetamine
dopamine release and, 399
Methylene blue
in mania, 941-le
Methylxanthines
neuroleptic treatment and, 642
Methysurgide
effect on prolactin response to ECT and, 465
Metyrapone
effect on ACTH response to human CRH in depression, 782
Monoamine(s)
metabolites, CSF, concentration gradient, in children and adolescents, 507
turnover, probenecid test for: correction, 960-le
Monoamine oxidase activity (MOA)
platelet, in alcoholism, 15
in premenstrual syndrome, 225
response to dexamethasone, in depression, 129
in schizophrenia, 63
Movement disorder
state-dependent, 945-le
MRI. *See* Magnetic resonance imaging
Music
tempo misperceptions in mania, 366-le
correction, 492

Naloxone
effect on eating behavior, in obesity, 483
reversal of attenuation of opiate abstinence syndrome, 886
Napping
cognitive influences on biological clock, 838
Natural killer cells
activity, in bereavement, 173
Neuroleptic(s)
behavioral effects, sensitization of, 950-le
binding to alpha$_1$ and D_2 receptors, 815
dopamine metabolites level in response to, 818
Neuroleptic malignant syndrome, 943-le
drug treatment withdrawal and, 368-le
Neuromodulators
stress-responsive, 371-ed
Neuropsychopharmacology
genetics and, 493-ed
Nicotine
panic attacks and, 365-le
subsensitivity, artificial light and, 437
tardive dyskinesia and, 364-le
Nifedipine
in depression, negative trial of, 958-le
Nocturnal penile tumescence
in depression, 33
Norepinephrine
/dopamine ratios, in schizophrenic brain, 79
modulation of gating of auditory evoked potentials by, 179

Obesity
effect of naloxone on eating behavior in, 483
Obsessive-compulsive disorder
frontal lobe dysfunction in, 602 (comment)
one-carbon cycle in, 721-le
One-carbon cycle
in obsessive-compulsive disorder, 721-le
Opiate abstinence syndrome
attenuation of, naloxone reversible, 886
Opioids
in cerebrospinal fluid, 649

Orofacial motor control
in schizophrenia and tardive dyskinesia, 787

P300
latency, alcoholism and, 310
Panic disorder
in alcohol withdrawal, 234
altered plasma dexamethasone and cortisol suppressibility in, 56
cortisol response to clonidine in, 322
GABAergic agents and, 942-le
HPA axis and treatment outcome, 762
isoproterenol-induced, 891
lactate-induced, tricyclic antidepressants and, 769
nicotine and, 365-le
nocturnal, in depressed patient, 432
TSH and catecholamine responses to TRH in, 87
Plasma exchange
for cerebral lupus erythematosus, 946-le
Platelet
membrane fluidity, in Alzheimer's disease, 918, 925
serotonergic mechanisms, alteration, in premenstrual syndrome, 225
Pneumonitis
aspiration, following electroconvulsive therapy, gastroparesis and, 812
Premenstrual syndrome
alteration of platelet serotonergic mechanisms and monoamine oxidase activity in, 225
treatment, verapamil for, 689
Probenecid
monoamine test: correction, 960-le
Prolactin
levels
in depression, 249, 268, 286
effect of chronic stress model of depression on, 447
plasma, bright light effects on, 843
sleep deprivation and, 631
response of ECT to, methysergide effects on, 465
Propranolol
for neuroleptic-induced akathisia, 823
Psychosis
epileptic, corpus callosum in, 857
pharmacological treatment of, 642
suicide and, 595
TSH response to TRH and haloperidol response in, 423

REM latency, in alcoholism, 25
REM sleep
deprivation, nocturnal cortisol release effects, 801

Schizoaffective disorders
psychophysiologic variables in, 741
Schizophrenia
chronic, neurologic soft signs in, 458
cognitive impairment in, 47
dopamine metabolites levels, in response to apomorphine and neuroleptics in, 818
dopamine/norepinephrine ratios in, 79
eye movements in, 747
eye tracking in, 675
familial and sporadic, visual evoked potential differences in, 828
gliosis in, 697, 727-le
haloperidol effects on cerebrospinal fluid acetylcholinesterase in, 701
limbic pathology in, 515
males, 50-msec latency auditory evoked field component in, 495
neuroleptic-induced akathisia in, propranolol for, 823
neuropathology of, 123-ed, 953-ed, 954-le (response)
orofacial motor control in, 787
platelet MAO activity in, 63
psychophysiologic variables in, 741
season of birth, computed tomography scan findings and, 461
sleep EEG variables in, 833
with tardive dyskinesia, asymmetric brain dysfunction in, 83
TRH test and DST in, 415
Seasonality
of birth, schizophrenia and, 461
Seizure
duration, in electroconvulsive therapy, 94
Serotinin
free, plasma levels, in autistic children and relatives, 488
levels, after suicide attempt, 725-le
uptake sites, 299
Serotonergic function
in diabetes, 234
Serotonergic mechanisms
platelet, in premenstrual syndrome, 225
Sleep
cognitive influences on biological clock, 838
deprivation
nocturnal TSH and prolactin secretion during, 631

total, in depressives, body core temperature in, 531
electroencephalogram, *See* Electroencephalogram
Smoking *See* Nicotine
Soft signs
neurologic, in chronic schizophrenia, 458
Somatostatin
cerebrospinal fluid levels, in Alzheimer's disease and depressed patients, 710
Stress
chronic, model of, in depression, LH and prolactin levels and, 447
posttraumatic, audiologic evaluation in, 522
prolactin levels and, 286
Suicide
attempted, serotinin levels following, 725-le
glutamine levels and, 723-le
by psychotics, 595

Tardive dyskinesia
magnetic resonance imaging in, 852
orofacial motor control in, 787
schizophrenia with, asymmetric brain dysfunction in, 83
smoking and, 364-le
Teaching
of psychiatry, 863-ed
Temperature
core, during total sleep deprivation in depressives, 531
Theophylline
effect on haloperidol-induced catalepsy, 642
Thyroid-stimulating hormone (TSH)
levels, sleep deprivation and, 631
response to TRH
in panic disorder, 87
in psychoses, 423
Thyrotropin-releasing hormone (TRH)
catecholamine response to, in panic disorder, 87
prolactin levels and, 249, 268
response of TSH to, in psychoses, 423
test, in schizoaffective mania, mania, and schizophrenia, 415
TSH response to
in panic disorder, 87
in psychosis, 423
Tourette's syndrome
plasma MHPG stability in, 391
Trace elements
serum levels, vanadium effects on, 775
TRH *See* Thyrotropin-releasing hormone
Tricyclic antidepressants
lactate-induced panic attacks and, 767
Tryptophan
bladder cancer and, 733-le
TSH *See* Thyroid-stimulating hormone

Uric acid
hyperactivity and, 344

Vanadium
serum levels, lithium effects on, 775
Ventricle. *See* Cerebral ventricle
Verapamil
treatment of premenstrual syndrome with, 689
Visual evoked potentials
in schizophrenia, 828

Weight loss
fluvoxamine and, 948-le

Zinc
CSF, in Alzheimer's type dementia, 480